Transforming growth factor-β-activated kinase 1 and pathological myocardial hypertrophy.
- Author:
Ying LI
1
;
Yue CHEN
1
;
Dong-Mei ZHANG
2
Author Information
1. Department of Physiology, Dalian Medical University, Dalian 116044, China.
2. Department of Physiology, Dalian Medical University, Dalian 116044, China. dongmeizhang72@163.com.
- Publication Type:Journal Article
- MeSH:
Cardiomegaly;
Humans;
MAP Kinase Kinase Kinases;
genetics;
Myocardium;
Phosphorylation;
Transforming Growth Factor beta;
Transforming Growth Factor beta1
- From:
Acta Physiologica Sinica
2020;72(4):499-505
- CountryChina
- Language:Chinese
-
Abstract:
The transforming growth factor-β-activated kinase 1 (TAK1) is a member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family. TAK1 plays important roles in many biological functions. Cardiac hypertrophy can be identified as physiological or pathological myocardial hypertrophy. TAK1 not only participates in the development of normal myocardium, but also plays an important role in regulating the occurrence and development of pathological myocardial hypertrophy. Angiotensin II (Ang II) or pressure overload induces pathological cardiac hypertrophy through different ways, such as hypoxia-inducible factor-1α (HIF-1α)-mediated transcriptional expression of TAK1, or transforming growth factor-β1 (TGF-β1)-, thyroid hormone-, ubiquitin protease-mediated TAK1 phosphorylation or ubiquitination. This article reviews the role of TAK1 in the occurrence and development of pathological myocardial hypertrophy and discusses the potential of TAK1 as an important target for the prevention and treatment of clinical myocardial hypertrophy.
